Genmab A/S R&D Update and ASH Data Review Transcript
/-- -
Hello, and welcome to Genmab's 2023 R&D Update and ASH Data Review. I'm Jan van de Winkel, President and CEO of Genmab, and I'm delighted to share with you some of the highlights for Genmab in 2023 as well as data from this year's ASH meeting. As always, we have a busy agenda. So, let's jump right in.
Next slide, please. As a reminder, this presentation may contain forward-looking statements, and as such, may contain certain risks and uncertainties.
Let's move to Slide 3. Genmab has a science-anchored and innovation-focused culture. Collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations and this slide acknowledges those relationships.
Let's move to our agenda on Slide 4. We will begin with a review of the excellent progress we made this year, as we advance towards our ambitious 2030 vision. Next, we will have a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |